Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone (Q47415788)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 July 2012

Language	Label	Description	Also known as
English	Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone	scientific article published on 2 July 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Bradley J. Monk

10

object named as

Bradley J Monk

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

author name string

Carolyn N Krasner

1

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Andres Poveda

2

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Thomas J Herzog

3

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Jan B Vermorken

4

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Stanley B Kaye

5

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Antonio Nieto

6

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Pilar Lardelli Claret

7

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Youn Choi Park

8

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Trilok Parekh

9

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

language of work or name

0 references

publication date

2 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

127

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

1

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

161-167

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Quality of life in patients with ovarian cancer: current state of research

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Test-retest reliability of health state valuations collected with the EuroQol questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Quality-of-life issues in the management of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.034

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YGYNO.2012.06.034

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

release_sntkmwx3nng53oxbddn6szghuq

1 reference

https://api.fatcat.wiki/v0/release/sntkmwx3nng53oxbddn6szghuq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/22765965

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47415788&oldid=2155929440"